Bio Reports
Kirin Holdings Company, Limited (Kirin Holdings) and Immunosens Co., Ltd. (Immunosens) have begun the joint development of a unique “Self-Testing Ser...
February 11, 2026 | News
Aucta Pharmaceuticals is pleased to announce the late January launch of PYQUVI oral suspension 22.75 mg/mL. PYQUVI, a corticosteroid indicated f...
February 10, 2026 | News
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that a new indication application for its TROP2-dir...
February 09, 2026 | News
New England Biolabs (NEB ®) will present several scientific posters at this week's Society for Laboratory Automation and Screening (SLAS) meeting in Bo...
February 09, 2026 | News
Kazia Therapeutics (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, announced co...
February 02, 2026 | News
Nine-month findings show mean improvement in Composite Unified Huntington's Disease Rating Scale from baseline of +0.64 points, compared to natural hi...
January 29, 2026 | News
Immunofoco, a clinical-stage biotechnology company advancing innovative CAR-T cell therapies for solid tumors, recently announced clinical data from ...
January 15, 2026 | News
The initial dosing occurred at Second Affiliated Hospital, Zhejiang University School of Medicine, under the leadership of Dr. Zhi-Ying Wu, head...
January 15, 2026 | News
Animate Biosciences announces positive preclinical results from a mouse model of pulmonary fibrosis demonstrating that two of its AI-designed therapeu...
January 15, 2026 | News
Doctors and researchers have made huge steps in treating this blood cancer lately. Yet, most people face a time when the cancer returns or stops responding...
January 14, 2026 | News
Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical stage innovative drug development company focused on develop...
January 13, 2026 | News
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable res...
January 12, 2026 | News
-The Phase II study for diabetes is a 13-week, randomized, double-blind, placebo-controlled and multi-center study to evaluate the effi...
January 06, 2026 | News
At the centre of this momentum stood the U.S. Food and Drug Administration, whose 2025 approvals illustrated how medicine is moving decisiv...
December 29, 2025 | Analysis | By arcilla.fran@biopharmaapac.com
Most Read
Bio Jobs
News
Editor Picks